Bezuclastinib

Name: Bezuclastinib in Nonadvanced systemic mastocytosis: Humanistic burden and health-related quality of life
Published: 2026-09-14T15:39:06-04:00

Nonadvanced systemic mastocytosis

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the second half of 2026
Last updated: September 17, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Nonadvanced systemic mastocytosis

Humanistic burden and health-related quality of life

1 evidence topic · 3 sources

Humanistic and productivity burden: U.S. systemic mastocytosis survey

“Over one half of patients (54%) reduced their work hours because of SM, and 64% avoided leaving home because of symptoms.” (opens the source at this quote in a new tab)